Effect of alpha-difluoromethylornithine alone and in combination with doxorubicin hydrochloride, cis-diamminedichloroplatinum (II), and vinblastine sulfate on the growth of P3J cells in vitro.
alpha-Difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, was examined as a single and combined agent in growth studies using P3J, a Burkitt's lymphoma cell line. Used alone, DFMO (greater than or equal to 50 micrograms/ml; 0.21 mM) prevents cell proliferation in liquid culture and reduces the number and size of colonies that form in a two-layer soft agar system. In combination studies in which the soft agar system was used, DFMO was used at 15 and 25 micrograms/ml, concentrations which reduced the number of colonies to approximately 65 and 50%, respectively, of control plates. When doxorubicin hydrochloride (Adriamycin) was combined with DFMO, synergistic effects were noted at both DFMO concentrations. Cisplatin and DFMO were synergistic at the higher DFMO concentration and were supraadditive at 15 micrograms DFMO/ml. Combination studies using vinblastine sulfate (Velban) with DFMO did not deviate significantly from the predicted additive response.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002051:Burkitt Lymphoma / Q000188:drug therapy* / Q000378:metabolism; D002453:Cell Cycle / Q000187:drug effects; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D002945:Cisplatin / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage; D004357:Drug Synergism; D000518:Eflornithine; D006801:Humans; D009952:Ornithine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D011073:Polyamines / Q000378:metabolism; D014747:Vinblastine / Q000008:administration & dosage
D011073:Polyamines; D014747:Vinblastine; D004317:Doxorubicin; D009952:Ornithine; D002945:Cisplatin; D000518:Eflornithine